

**Marion Johnson: General Discussion**  
**Agenda for Meeting w/ Marietta Echeverria, RD Acting Director**  
**February 10, 2022**

**CHEMICAL UPDATES:**

**Flonicamid/Cyclaniliprole** –ISK Biosciences  
PRIA Date: 2/17/2022 (Needs renegotiating soon)

\*Carmen, Debra, and I met on yesterday (2/9/22) to go over the slight modifications per OGC's suggestions and changes were concurred upon. We will work with IVB1 to coordinate documents and prepare to send to the RD/IO concurrently.

**Ex. 5 Deliberative Process (DP)**

**Diiflufenacan** – JR. David Gardner will be assisting FHB with the remaining processing of this new chemical, but the chemical will remain with FHB once registered. FHB will be scheduling a meeting to assist with the temporary transfer of information, etc.

**Pyrifluquinazon/PFAS** –  
**First Residential Outdoor Uses for Ornamental shrubs, trees, etc., Nichino**  
Current PRIA Date: 3/11/22 (Reneg)

\*Reconnected with Jeff Dawson this week, so we'll be talking this week with a focus on the import.

Additional discussions with Jenn on broflanilide language regarding PFAS to continue. I have a follow-up question for Jenn pending.

**Ex. 5 Deliberative Process (DP)**

**Isocycloseram** – Syngenta new A.I  
PRIA date: 1/17/23  
*Nothing new:*

**Ex. 5 Deliberative Process (DP)**

## Ex. 5 Deliberative Process (DP)

### **Spiropidion – New A.I. from Syngenta for Imports**

PRIA date: 8/5/22

This week, a detailed letter was sent to Syngenta requesting that they respond to lack of labeling directions (to include application rates) for the additional crops within a crop grouping, where only the representative crop information was provided.

## Ex. 5 Deliberative Process (DP)

### **Acenonapyr – Gowan**

Working with OGC on data submission and citations where Nisso has requested that no information be shared with the applicant Gowan, even though Gowan is using Nisso's data from the technical source.

### **Reclassification of d-limonene by Bioclassification Committee**

\*Memo is with the RD/IO for review.

~~Upon recent review of the memo, it seems that there were mainly two comments provided by BPPD at the BC level and we have addressed those concerns to the best of our knowledge and findings. We will be sending that information again to the RD/IO for review/concurrence.~~

### **Aldicarb Cancellation Order – Completed**

## Ex. 5 Deliberative Process (DP)

## Ex. 5 Deliberative Process (DP)

### VARIOUS PROJECT INITIATIVES

\*Eric Kraft and I have finalized our brief comments on the CRP Charter, so I anticipate that Vanessa will be sending the charter to the RD/IO, shortly.

\*Drafting document to clarify RD's needs for centralized electronic archiving of e-records, as we begin to transition back to the physical workspace.

Frequent meetings (i.e., bi-weekly to monthly) are occurring with OPS/IRMD and Guynin Myers on purchasing, travel, and associated efforts. Betty was instrumental in setting this up.

### IVB2 PERSONNEL CHANGES, WORKLOAD BALANCE, HIRING CHALLENGES:

## Ex. 5 Deliberative Process (DP)